Responses
Clinical/translational cancer immunotherapy
Original research
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
